Masimo Corp. Reaches New 12-Month High at $29.98 (MASI)
Masimo Corp. (NASDAQ:MASI)’s share price reached a new 52-week high on Friday, American Banking and Market News reports. The company traded as high as $29.98 and last traded at $29.95, with a volume of 333,701 shares traded. The stock had previously closed at $29.05.
A number of research firms have recently commented on MASI. Analysts at Roth Capital raised their price target on shares of Masimo Corp. from $29.00 to $32.00 in a research note to investors on Thursday, October 31st. They now have a “buy” rating on the stock. Separately, analysts at Feltl & Co. raised their price target on shares of Masimo Corp. from $22.00 to $26.00 in a research note to investors on Thursday, October 31st. They now have a “hold” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Masimo Corp. in a research note to investors on Thursday, October 31st. They now have a $30.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. Masimo Corp. currently has a consensus rating of “Hold” and an average price target of $28.00.
Masimo Corp. has a one year low of $19.03 and a one year high of $29.66. The stock’s 50-day moving average is $28.67 and its 200-day moving average is $26.00. The company has a market cap of $1.693 billion and a P/E ratio of 26.17.
Masimo Corp. (NASDAQ:MASI) last announced its earnings results on Wednesday, October 30th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.01. The company had revenue of $131.40 million for the quarter, compared to the consensus estimate of $132.47 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis.
Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.